ArticleThe Journal of antimicrobial chemotherapy2014
Discovery of novel mutations for clarithromycin resistance in Helicobacter pylori by using next-generation sequencing.
Article in The Journal of antimicrobial chemotherapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 81 citations in OpenAlex.
- Synonymous codon-optimized multiplex qPCR for simultaneous detection ofJournal of clinical microbiology · 2026Article
- Low-Abundance and FragmentaryBiomolecules · 2026Article
- Whole genome sequence analysis ofiScience · 2025Article
- Article
- Targeted nanomedicines for the treatment ofMaterials today. Bio · 2025Review
- Development of a High-Resolution Melting Method for the Detection of Clarithromycin-ResistantAntibiotics (Basel, Switzerland) · 2024Article
- First insight into the whole genome sequence variations in clarithromycin resistant Helicobacter pylori clinical isolates in Russia.Scientific reports · 2024Article
- Exploring the Molecular Mechanisms of Macrolide Resistance in Laboratory MutantAntibiotics (Basel, Switzerland) · 2024Article
- Testing forJournal of clinical microbiology · 2024Review
- Antibiotic Resistance ofJournal of Korean medical science · 2024Review
- Prevalence of Clarithromycin-Resistant Helicobacter pylori Strains in Zambia: A Sub-Saharan African Country.Digestive diseases (Basel, Switzerland) · 2024Article
- Types of 23S Ribosomal RNA Point Mutations AffectingThe Korean journal of helicobacter and upper gastrointestinal research · 2023Article
- Antibiotic Resistance, Susceptibility Testing and Stewardship inInternational journal of molecular sciences · 2023Review
- Antibiotic resistance in Helicobacter pylori: From potential biomolecular mechanisms to clinical practice.Journal of clinical laboratory analysis · 2023Review
- Mutations Related to Antibiotics Resistance inAntibiotics (Basel, Switzerland) · 2023Article
- Application of biomaterials in the eradication ofFrontiers in microbiology · 2023Review
- Assessment of Helicobacter pylori positive infected patients according to Clarithromycin resistant 23S rRNA, rpl22 associated mutations and cyp2c19*1, *2, *3 genes pattern in the Early stage of Gastritis.BMC research notes · 2022Article
- Clinical Implications ofAntibiotics (Basel, Switzerland) · 2022Review
- Environmental complexity is more important than mutation in driving the evolution of latent novel traits in E. coli.Nature communications · 2022Article
- Molecular characterization ofSaudi medical journal · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 3 countries.
Funding
Abstract
objectivesResistance to clarithromycin is the most important factor causing failure of Helicobacter pylori eradication. Although clarithromycin resistance is mainly associated with three point mutations in the 23S rRNA genes, it is unclear whether other mutations are associated with this resistance.
methodsTwo types of clarithromycin-resistant strains (low- and high-resistance strains) were obtained from clarithromycin-susceptible H. pylori following exposure to low clarithromycin concentrations. The genome sequences were determined with a next-generation sequencer. Natural transformation was used to introduce the candidate mutations into strain 26695. Etest and an agar dilution method were used to determine the MICs.
resultsHigh-resistance strains contained the mutation A2143G in the 23S rRNA genes, whereas low-resistance strains did not. There were seven candidate mutations in six genes outside of the 23S rRNA genes. The mutated sequences in hp1048 (infB), hp1314 (rpl22) and the 23S rRNA gene were successfully transformed into strain 26695 and the transformants showed an increased MIC of and low resistance to clarithromycin. The transformants containing a single mutation in infB or rpl22 (either a 9 bp insertion or a 3 bp deletion) or the 23S rRNA gene showed low MICs (0.5, 2.0, 4.0 and 32 mg/L, respectively) while the transformants containing double mutations (mutation in the 23S rRNA genes and mutation in infB or rpl22) showed higher MICs (>256 mg/L).
conclusionsNext-generation sequencing can be a useful tool for screening mutations related to drug resistance. We discovered novel mutations related to clarithromycin resistance in H. pylori (infB and rpl22), which have synergic effects with 23S rRNA resulting in higher MICs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.